Air Liquide announced that it has entered into exclusive negotiations with EQT, a global investment organization, for the potential sale of its subsidiary Schülke & Mayr GmbH.
This potential sale, as previously announced in November 2019, illustrates Air Liquide’s strategy to review its business portfolio regularly and to focus on its core gases and healthcare businesses, thereby enhancing Air Liquide’s performance.
Air Liquide intends to continue to develop its healthcare activities, while providing Schülke & Mayr GmbH with the best opportunity for its long-term development.
If completed, the acquisition by EQT VIII fund will further support Schülke & Mayr GmbH’s next phase of growth and its innovation development.
This transaction is subject to the final and definitive agreement between the parties, and will be carried out in the framework of the relevant social processes including ongoing dialogue with the employee representatives’ bodies. Furthermore, the transaction will be subject to antitrust and foreign investment clearances.